• Product NameLinagliptin
• Brief DescriptionInhibitors
• Purification99.63%
• Biological ActivityLinagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Two pharmacological characteristics that sets linagliptin apart from other DPP-4 inhibitors is that it has a non-linear pharmacokinetic profile and is not primarily eliminated by the renal system. FDA approved on May 2, 2011.
• Target NameDPP-4 inhibitor
• CAS No. 668270-12-0
• Calculated MW 472.54
• Formulation C25H28N8O2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Metabolism system
  SMILES:CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
  Pathways:Proteases/Proteasome
  Receptor:DPP-4
  Boling pt:661.189C
  Melting pt:202C
  Solubility:Ethanol: 1 mg/mL (2.11 mM); DMSO: 17 mg/mL (35.97 mM)
  Appearance:Off-white Color Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Forst T, Pfutzner A. Expert Opin PharmacOthers. 2012 Jan;13(1):101-10.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting